MAP2K1 and cutaneous melanoma: Great strides have been made over the past 10 years in the treatment of cutaneous melanoma particularly in the use of checkpoint inhibitory immunotherapy and in tumors expressing mutant B-RAF V600E, the combined use of B-RAF and MEK1/2 inhibitors (1, 2).